Statins impair CD1d-mediated antigen presentation through the inhibition of prenylation

Journal of Immunology

Volumn 182, Issue 8, 2009, Pages 4744-4750

  Khan, Masood A ^a,b   Gallo, Richard M ^a,b   Renukaradhya, Gourapura J ^a,b   Du, Wenjun ^c   Gervay Hague, Jacquelyn ^c   Brutkiewicz, Randy R ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WALTHER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; SIMVASTATIN; HLA ANTIGEN CLASS 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTATION; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; INNATE IMMUNITY; ISOPRENYLATION; MOUSE; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; T LYMPHOCYTE; WESTERN BLOTTING; ANIMAL; CELL CULTURE; COCULTURE; DRUG EFFECT; IMMUNOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, CD1D; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MEVALONIC ACID; MICE; PRENYLATION;

EID: 65249182726     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804311     Document Type: Article

References (54)

1. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
2. Arnaud, C., N. R. Veillard, and F. Mach. 2005. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis. Curr. Drug Targets 5: 127-134. (Pubitemid 40645486)
3. Goldstein, M. R., L. Mascitelli, and F. Pezzetta. 2008. The double-edged sword of statin immunomodulation. Int. J. Cardiol. In press.
4. Wierzbicki, A. S., R. Poston, and A. Ferro. 2003. The lipid and non-lipid effects of statins. Pharmacol. Ther. 99: 95-112.
5. Yoshida, M. 2003. Potential role of statins in inflammation and atherosclerosis. J. Atheroscler. Thromb. 10: 140-144. (Pubitemid 36961806)
6. Liao, J. K., and U. Laufs. 2005. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45: 89-118.
7. Zhang, F. L., and P. J. Casey. 1996. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65: 241-269. (Pubitemid 26250610)
8. Bifulco, M. 2005. Role of the isoprenoid pathway in ras transforming activity, cytoskeleton organization, cell proliferation and apoptosis. Life Sci. 77: 1740-1749. (Pubitemid 41073667)
9. Konstantinopoulos, P. A., M. V. Karamouzis, and A. G. Papavassiliou. 2007. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat. Rev. Drug Discov. 6: 541-555.
10. Cordle, A., J. Koenigsknecht-Talboo, B. Wilkinson, A. Limpert, and G. Landreth. 2005. Mechanisms of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280: 34202-34209. (Pubitemid 41443145)
11. Kuipers, H. F., and P. J. van den Elsen. 2007. Immunomodulation by statins: inhibition of cholesterol vs. isoprenoid biosynthesis. Biomed. Pharmacother. 61: 400-407.
12. Niessner, A., S. Steiner, W. S. Speidl, J. Pleiner, D. Seidinger, G. Maurer, J. J. Goronzy, C. M. Weyand, C. W. Kopp, K. Huber, et al. 2006. Simvastatin suppresses endotoxin-induced upregulation of Toll-like receptors 4 and 2 in vivo. Atherosclerosis 189: 408-413. (Pubitemid 44634488)
13. Ghittoni, R., L. Patrussi, K. Pirozzi, M. Pellegrini, P. E. Lazzerini, P. L. Capecchi, F. L. Pasini, and C. T. Baldari. 2005. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19: 605-607. (Pubitemid 40471259)
14. Yilmaz, A., C. Reiss, O. Tantawi, A. Weng, C. Stumpf, D. Raaz, J. Ludwig, T. Berger, A. Steinkasserer, W. G. Daniel, and C. D. Garlichs. 2004. HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172: 85-93. (Pubitemid 38058605)
15. Greenwood, J., L. Steinman, and S. S. Zamvil. 2006. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat. Rev. Immunol. 6: 358-370.
16. Martin-Ventura, J. L., L. M. Blanco-Colio, A. Gomez-Hernandez, B. Munoz-Garcia, M. Vega, J. Serrano, L. Ortega, G. Hernandez, J. Tunon, and J. Egido. 2005. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36: 1796-1800.
17. Bustos, C., M. A. Hernandez-Presa, M. Ortego, J. Tunon, L. Ortega, F. Perez, C. Diaz, G. Hernandez, and J. Egido. 1998. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J. Am. Coll. Cardiol. 32: 2057-2064. (Pubitemid 29010476)
18. Hillyard, D. Z., C. D. Nutt, J. Thomson, K. J. McDonald, R. K. Wan, A. J. Cameron, P. B. Mark, and A. G. Jardine. 2007. Statins inhibit NK cell cytotoxicity by membrane raft depletion rather than inhibition of isoprenylation. Atherosclerosis 191: 319-325.
19. Brutkiewicz, R. R., Y. Lin, S. Cho, Y. K. Hwang, V. Sriram, and T. J. Roberts. 2003. CD1d-mediated antigen presentation to natural killer T (NKT) cells. Crit. Rev. Immunol. 23: 403-419.
20. Van Kaer, L. 2007. NKT cells: T lymphocytes with innate effector functions. Curr. Opin. Immunol. 19: 354-364. (Pubitemid 46687006)
21. Brutkiewicz, R. R. 2006. CD1d ligands: the good, the bad, and the ugly. J. Immunol. 177: 769-775.
22. Tupin, E., A. Nicoletti, R. Elhage, M. Rudling, H. G. Ljunggren, G. K. Hansson, and G. P. Berne. 2004. CD1d-dependent activation of NKT cells aggravates atherosclerosis. J. Exp. Med. 199: 417-422. (Pubitemid 38252053)
23. Robertson, A. K., and G. K. Hansson. 2006. T cells in atherogenesis: for better or for worse? Arterioscler. Thromb. Vasc. Biol. 26: 2421-2432.
24. Galkina, E., and K. Ley. 2007. Leukocyte influx in atherosclerosis. Curr. Drug Targets 8: 1239-1248.
25. Mercer, J. C., M. J. Ragin, and A. August. 2005. Natural killer T cells: rapid responders controlling immunity and disease. Int. J. Biochem. Cell Biol. 37: 1337-1343. (Pubitemid 40502005)
26. Chan, W. L., N. Pejnovic, T. V. Liew, C. A. Lee, R. Groves, and H. Hamilton. 2003. NKT cell subsets in infection and inflammation. Immunol. Lett. 85: 159-163. (Pubitemid 36071571)
27. Yilmaz, A., M. Lochno, F. Traeg, I. Cicha, C. Reiss, C. Stumpf, D. Raaz, T. Anger, K. Amann, T. Probst, et al. 2004. Emergence of dendritic cells in rupture-prone regions of vulnerable carotid plaques. Atherosclerosis 176: 101-110. (Pubitemid 39078651)
28. Rogers, L., S. Burchat, J. Gage, M. Hasu, M. Thabet, L. Wilcox, T. A. Ramsamy, and S. C. Whitman. 2008. Deficiency of invariant Vα14 natural killer T cells decreases atherosclerosis in LDL receptor null mice. Cardiovasc. Res. 78: 167-174. (Pubitemid 351430959)
29. VanderLaan, P. A., C. A. Reardon, Y. Sagiv, L. Blachowicz, J. Lukens, M. Nissenbaum, C. R. Wang, and G. S. Getz. 2007. Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosis. Am. J. Pathol. 170: 1100-1107.
30. Nakai, Y., K. Iwabuchi, S. Fujii, N. Ishimori, N. Dashtsoodol, K. Watano, T. Mishima, C. Iwabuchi, S. Tanaka, J. S. Bezbradica, et al. 2004. Natural killer T cells accelerate atherogenesis in mice. Blood 104: 2051-2059. (Pubitemid 39297856)
31. Bobryshev, Y. V., and R. S. Lord. 2005. Co-accumulation of dendritic cells and natural killer T cells within rupture-prone regions in human atherosclerotic plaques. J. Histochem. Cytochem. 53: 781-785.
32. Melian, A., Y. J. Geng, G. K. Sukhova, P. Libby, and S. A. Porcelli. 1999. CD1 expression in human atherosclerosis: a potential mechanism for T cell activation by foam cells. Am. J. Pathol. 155: 775-786. (Pubitemid 29426823)
33. Chan, W. L., N. Pejnovic, H. Hamilton, T. V. Liew, D. Popadic, A. Poggi, and S. M. Khan. 2005. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ. Res. 96: 675-683.
34. Libby, P., and M. Aikawa. 2003. Mechanisms of plaque stabilization with statins. Am J. Cardiol. 91: 4B-8B.
35. Dilaveris, P., G. Giannopoulos, M. Riga, A. Synetos, and C. Stefanadis. 2007. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr. Vasc. Pharmacol. 5: 227-237.
36. Ghittoni, R., G. Napolitani, D. Benati, C. Ulivieri, L. Patrussi, F. Laghi Pasini, A. Lanzavecchia, and C. T. Baldari. 2006. Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur. J. Immunol. 36: 2885-2893. (Pubitemid 44782562)
37. Shimabukuro-Vornhagen, A., T. Liebig, and M. von Bergwelt-Baildon. 2008. Statins inhibit human APC function: implications for the treatment of GVHD. Blood 112: 1544-1545.
38. Brutkiewicz, R. R., C. A. Willard, K. K. Gillett-Heacock, M. R. Pawlak, J. C. Bailey, M. A. Khan, M. Nagala, W. Du, J. Gervay-Hague, and G. J. Renukaradhya. 2007. Protein kinase Cδ is a critical regulator of CD1d-mediated antigen presentation. Eur. J. Immunol. 37: 2390-2395. (Pubitemid 47430431)
39. Roberts, T. J., V. Sriram, P. M. Spence, M. Gui, K. Hayakawa, I. Bacik, J. R. Bennink, J. W. Yewdell, and R. R. Brutkiewicz. 2002. Recycling CD1d1 molecules present endogenous antigens processed in an endocytic compartment to NKT cells. J. Immunol. 168: 5409-5414.
40. + T cell lymphoma by natural killer T (NKT) cells. Proc. Natl. Acad. Sci. USA 99: 8197-8202.
41. Renukaradhya, G. J., T. J. Webb, M. A. Khan, Y. L. Lin, W. Du, J. Gervay-Hague, and R. R. Brutkiewicz. 2005. Virus-induced inhibition of CD1d1-mediated antigen presentation: reciprocal regulation by p38 and ERK. J. Immunol. 175: 4301-4308.
42. Roy, K. C., I. Maricic, A. Khurana, T. R. Smith, R. C. Halder, and V. Kumar. 2008. Involvement of secretory and endosomal compartments in presentation of an exogenous self-glycolipid to type II NKT cells. J. Immunol. 180: 2942-2950.
43. Buhaescu, I., and H. Izzedine. 2007. Mevalonate pathway: a review of clinical and therapeutical implications. Clin. Biochem. 40: 575-584. (Pubitemid 46829082)
44. Lane, K. T., and L. S. Beese. 2006. Thematic review series: lipid posttranslational modifications: structural biology of protein farnesyltransferase and geranylgera-nyltransferase type I. J. Lipid Res. 47: 681-699.
45. Liao, J. K. 2004. Statin therapy: having the good without the bad. Hypertension 43: 1171-1172.
46. Hakamada-Taguchi, R., Y. Uehara, K. Kuribayashi, A. Numabe, K. Saito, H. Negoro, T. Fujita, T. Toyo-oka, and T. Kato. 2003. Inhibition of hydroxym-ethylglutaryl-coenzyme A reductase reduces Th1 development and promotes Th2 development. Circ. Res. 93: 948-956. (Pubitemid 37441285)
47. Ostrowski, S. M., B. L. Wilkinson, T. E. Golde, and G. Landreth. 2007. Statins reduce amyloid-β production through inhibition of protein isoprenylation. J. Biol. Chem. 282: 26832-26844.
48. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
49. Major, A. S., R. R. Singh, S. Joyce, and L. Van Kaer. 2006. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol. Res. 34: 49-66. (Pubitemid 43780376)
50. Bobryshev, Y. V., and R. S. Lord. 1998. Mapping of vascular dendritic cells in atherosclerotic arteries suggests their involvement in local immune-inflammatory reactions. Cardiovasc. Res. 37: 799-810.
51. Bobryshev, Y. V., and R. S. Lord. 2002. Expression of heat shock protein-70 by dendritic cells in the arterial intima and its potential significance in atherogenesis. J. Vasc. Surg. 35: 368-375.
52. Corsini, A., S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini. 1999. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84: 413-428.
53. Ait-Oufella, H., B. L. Salomon, S. Potteaux, A. K. Robertson, P. Gourdy, J. Zoll, R. Merval, B. Esposito, J. L. Cohen, S. Fisson, et al. 2006. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12: 178-180. (Pubitemid 43214743)
54. + T cells. Atherosclerosis 197:829-839.